Tetravalent HPV recombinant cervical cancer vaccine reduces infection and lesions in women under 45 years of age

, the latest data revealed at the 24th International Conference on Papillomavirus (IPC) in Beijing showed that inwomen aged 24 to 45, the quadrouted human papillomavirus (6, 11, 16) developed by Mercado compared to the placeboType 18) Recombinant Cervical Cancer Vaccine (GARDASIL) can effectively prevent 91% of persistent infections caused by the 6, 11, 16, 18 human papillomavirus (HPV), low cervical lesions, precancerous and genital lesionsHuman papillomavirus (HPV) has more than 100 types, most of which are relatively harmless, of which type 6, 11, 16, 18 is the cause of cervical cancer, genital warts, more than two-thirds of cervical cancer cases are caused by high-risk HPV 16 and 18The international multicenter study aims to test the efficacy of GARDASIL in reducing theand infection ofdiseases caused by HPV 6, 11, 16 and 18More than 3,800womenparticipating in the clinical trials, all of which were aged between 20 and 45, and about 31% were from AsiaNone of thesewomenhad undergone a cervical electrocution or hysterectomy, and had no of HPV-related
diseases confirmed by biopsy in the past five years, nor had a history of genital wartsSince GARDASIL was designed to preventofdisease caused by HPV 6, 11, 16 and 18, rather than treating infections, the main population in the study was female subjects who were not infected with any of the four types of HPV at the beginning of the study, remained associated with HPV infection throughout the vaccination process, and were given all three placebo and vaccinationsTHE RESEARCHERS ANALYZED GARDASIL'S PERSISTENT INFECTIONS CAUSED BY FOUR TYPES OF HPV (TYPE 6, 11, 16, 18), CERVICAL EPITHELIOMA VARIANTS (CIN) OR GENITAL LESIONS, AND THE COMBINED INCIDENCE OF DISEASES CAUSED BY TYPES 16 AND 18 OF HPVAt the primary end of the study, after an average of 1.65 years of follow-up, the placebo group had 41 cases of persistent infection, CIN or genital lesions (genital warts and vulva and vaginal lesions) caused by type S6, 11, 16, 18, CIN or genital lesions (genital warts and vulva lesions); Also as a primary endpoint, the study showed that GARDASIL prevented 83% of persistent infections caused by HPV16 and 18, low cervical lesions, precancerous lesions and genital lesions (23 cases in the placebo group and 4 in the vaccine group)For a secondary study, GARDASIL prevented 100% of persistent infections caused by HPV6 and 11, low cervical lesions, precancerous lesions and genital lesionsIn this study, the most common adverse events associated with the injection site were higher than in the placebo group (76.4% and 64.2%, respectively)GARDASIL is currently suitable for women aged 9 to 26 years, can prevent cervical cancer caused by type 6, 11, 16, 18 HPV, precancerous lesions or non-typical increase in disease, and genital wartsMercatom plans to submit the data to the U.SFDA by the end of this year, with a view to getting approval to extend its vaccine adaptation to women under the age of 45(Wang Dan)